CN1951432A - 参附组合物、制剂及其制备方法和用途 - Google Patents
参附组合物、制剂及其制备方法和用途 Download PDFInfo
- Publication number
- CN1951432A CN1951432A CN 200610153577 CN200610153577A CN1951432A CN 1951432 A CN1951432 A CN 1951432A CN 200610153577 CN200610153577 CN 200610153577 CN 200610153577 A CN200610153577 A CN 200610153577A CN 1951432 A CN1951432 A CN 1951432A
- Authority
- CN
- China
- Prior art keywords
- ginseng
- aconiti lateralis
- radix
- lateralis preparata
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 79
- 241000173529 Aconitum napellus Species 0.000 title claims description 66
- 229940023019 aconite Drugs 0.000 title claims description 66
- 238000002360 preparation method Methods 0.000 title claims description 48
- 235000008434 ginseng Nutrition 0.000 claims abstract description 103
- 241000208340 Araliaceae Species 0.000 claims abstract description 102
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 101
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 101
- 229930013930 alkaloid Natural products 0.000 claims abstract description 37
- 239000000284 extract Substances 0.000 claims abstract description 27
- 150000003797 alkaloid derivatives Chemical class 0.000 claims abstract description 21
- 230000035939 shock Effects 0.000 claims abstract description 15
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 claims abstract description 6
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940039750 aconitine Drugs 0.000 claims abstract description 6
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 claims abstract description 6
- 206010007625 cardiogenic shock Diseases 0.000 claims abstract description 5
- 208000015181 infectious disease Diseases 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 60
- 239000003814 drug Substances 0.000 claims description 30
- 238000010828 elution Methods 0.000 claims description 22
- 235000020710 ginseng extract Nutrition 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 229930182490 saponin Natural products 0.000 claims description 17
- 150000007949 saponins Chemical class 0.000 claims description 17
- 235000017709 saponins Nutrition 0.000 claims description 17
- 239000011347 resin Substances 0.000 claims description 16
- 229920005989 resin Polymers 0.000 claims description 16
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 238000001556 precipitation Methods 0.000 claims description 12
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims description 10
- 206010049771 Shock haemorrhagic Diseases 0.000 claims description 10
- 239000012535 impurity Substances 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 239000003513 alkali Substances 0.000 claims description 6
- 229910021529 ammonia Inorganic materials 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000012567 medical material Substances 0.000 claims description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- DPMGVDIWDTYPMP-UHFFFAOYSA-N Hypaconitine Natural products COCC12CCC(OC)C3(CN(C)C1)C4CC5(O)C(OC)C(O)C(CC(OC)C23)(OC(=O)C)C4C5OC(=O)c6ccccc6 DPMGVDIWDTYPMP-UHFFFAOYSA-N 0.000 claims description 4
- 230000000274 adsorptive effect Effects 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 230000006837 decompression Effects 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- FIDOCHXHMJHKRW-GKVQVCCJSA-N hypaconitine Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@]45[C@@H](OC)CC[C@@]6([C@H]4[C@@H](OC)[C@H]([C@@](OC(C)=O)([C@H]31)[C@@H](O)[C@H]2OC)[C@H]5N(C)C6)COC)C(=O)C1=CC=CC=C1 FIDOCHXHMJHKRW-GKVQVCCJSA-N 0.000 claims description 4
- 238000005325 percolation Methods 0.000 claims description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 239000004952 Polyamide Substances 0.000 claims description 3
- 239000003463 adsorbent Substances 0.000 claims description 3
- 238000005352 clarification Methods 0.000 claims description 3
- 238000006073 displacement reaction Methods 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 229920002647 polyamide Polymers 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 241000227129 Aconitum Species 0.000 abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 2
- 150000005690 diesters Chemical class 0.000 abstract description 2
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 239000009798 Shen-Fu Substances 0.000 description 30
- 241000700159 Rattus Species 0.000 description 27
- 230000036772 blood pressure Effects 0.000 description 22
- 239000000243 solution Substances 0.000 description 18
- 229940079593 drug Drugs 0.000 description 17
- 239000007924 injection Substances 0.000 description 15
- 238000002347 injection Methods 0.000 description 15
- 206010019280 Heart failures Diseases 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 5
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 229940023488 pill Drugs 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- 239000002826 coolant Substances 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000007914 intraventricular administration Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 238000012109 statistical procedure Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- LVVKXRQZSRUVPY-HNNXBMFYSA-N (S)-coclaurine Chemical compound C([C@@H]1NCCC=2C=C(C(=CC=21)O)OC)C1=CC=C(O)C=C1 LVVKXRQZSRUVPY-HNNXBMFYSA-N 0.000 description 2
- 241001671653 Aconitum carmichaelii Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010007558 Cardiac failure chronic Diseases 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 240000004371 Panax ginseng Species 0.000 description 2
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- 206010034568 Peripheral coldness Diseases 0.000 description 2
- 239000000980 acid dye Substances 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940085826 captopril 12.5 mg Drugs 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 239000007766 cera flava Substances 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000011162 core material Substances 0.000 description 2
- -1 di esters alkaloid Chemical class 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000011265 semifinished product Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- IBRKLUSXDYATLG-LURJTMIESA-N (S)-salsolinol Chemical compound OC1=C(O)C=C2[C@H](C)NCCC2=C1 IBRKLUSXDYATLG-LURJTMIESA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000205571 Caulophyllum Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 210000004903 cardiac system Anatomy 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000018299 prostration Diseases 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229940074569 salsolinol Drugs 0.000 description 1
- IBRKLUSXDYATLG-UHFFFAOYSA-N salsolinol hydrobromide Natural products OC1=C(O)C=C2C(C)NCCC2=C1 IBRKLUSXDYATLG-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 剂量(mg/kg) | 造模前血压(mmhg) | 造模后血压(mmHg) | ||
正常组 | 126±8 | 60min | 120min | 240min | |
125±9 | 126±7 | 120±11 | |||
NS | --- | 125±9 | 72±8 | 68±8 | 74±10 |
地塞米松 | 12.5mg/kg | 127±11 | 89±10ΔΔ | 82±9ΔΔ | 88±9ΔΔ |
999参附注射液 | 5ml/kg | 126±11 | 80±6Δ | 77±7Δ | 83±6Δ |
人参附子组合物 | 5mg/kg | 126±10 | 81±6Δ | 78±7Δ | 84±6Δ |
16mg/kg | 123±10 | 88±10ΔΔ* | 85±8ΔΔ* | 90±6ΔΔ* | |
48mg/kg | 126±12 | 89±16ΔΔ | 86±11ΔΔ | 91±14ΔΔ | |
100mg/kg | 125±11 | 91±7ΔΔ | 97±8ΔΔ | 91±7ΔΔ | |
160mg/kg | 123±11 | 92±7ΔΔ | 97±7ΔΔ | 92±7ΔΔ |
组别 | 剂量 | LVSP(mmHg) | +dp/dtmax(mmHg/s) | -dp/dtmax(mmHg/s) | Vpm(/s) |
正常对照组 | 82.9±15.1 | 8054±616 | -4754±752 | 1676±243 | |
NS组 | 55.5±8.0 | 3749±232 | -2549±232 | 705±72 | |
卡托普利 | 12.5mg/kg | 66.9±7.5ΔΔ | 4004±229Δ | -2798±232Δ | 820±66ΔΔ |
999参附注射液 | 5ml/kg | 63.0±7.5Δ | 4009±289Δ | -2798±248Δ | 805±72ΔΔ |
人参附子组合物 | 5mg/kg | 63.5±7.0Δ | 4010±285Δ | -2797±230Δ | 810±72ΔΔ |
16mg/kg | 71.0±8.8ΔΔ* | 4269±236ΔΔ* | -3001±176ΔΔ* | 870±63ΔΔ* | |
48mg/kg | 72.0±8.8ΔΔ | 4439±242ΔΔ | -3049±230ΔΔ | 900±67ΔΔ | |
100mg/kg | 74.0±8.7ΔΔ | 4759±227ΔΔ | -3148±231ΔΔ | 1005±60ΔΔ | |
160mg/kg | 75.0±8.7ΔΔ | 4780±227ΔΔ | -3150±231ΔΔ | 1035±60ΔΔ |
组别 | 剂量(mg/kg) | 造模前血压(mmhg) | 造模后血压(mmHg) | ||
60min | 120min | 240min | |||
正常对照组 | 125±8 | 123±8 | 126±5 | 126±10 | |
NS | 125±10 | 54±8 | 59±8 | 64±8 | |
盐酸肾上腺素组 | 0.1mg/kg | 127±12 | 82±9ΔΔ | 87±9ΔΔ | 88±9ΔΔ |
999参附注射液 | 5ml/kg | 126±13 | 61±8Δ | 67±7Δ | 72±8Δ |
人参附子组合物 | 5mg/kg | 126±15 | 61±7Δ | 68±7Δ | 72±6Δ |
16mg/kg | 123±14 | 68±5ΔΔ* | 73±5ΔΔ* | 78±5ΔΔ* | |
48mg/kg | 125±12 | 69±8ΔΔ | 74±7ΔΔ | 80±8ΔΔ | |
100mg/kg | 124±11 | 72±7ΔΔ | 76±8ΔΔ | 81±7ΔΔ | |
160mg/kg | 124±10 | 74±7ΔΔ | 77±8ΔΔ | 82±7ΔΔ |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006101535771A CN1951432B (zh) | 2005-09-13 | 2006-09-12 | 参附组合物、制剂及其制备方法和用途 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510044704 | 2005-09-13 | ||
CN200510044704.X | 2005-09-13 | ||
CN2006101535771A CN1951432B (zh) | 2005-09-13 | 2006-09-12 | 参附组合物、制剂及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1951432A true CN1951432A (zh) | 2007-04-25 |
CN1951432B CN1951432B (zh) | 2011-12-21 |
Family
ID=38058112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006101535771A Expired - Fee Related CN1951432B (zh) | 2005-09-13 | 2006-09-12 | 参附组合物、制剂及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1951432B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102283913A (zh) * | 2011-09-08 | 2011-12-21 | 四川省中医药科学院 | 附子提取物及其应用 |
CN101697986B (zh) * | 2007-05-31 | 2012-01-25 | 北京和润创新医药科技发展有限公司 | 一种用离子交换树脂分离长春花总生物碱的方法 |
CN113281448A (zh) * | 2021-05-22 | 2021-08-20 | 江西中医药大学 | 基于心源性休克大鼠模型的代谢组学分析方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110169952B (zh) * | 2019-06-26 | 2021-07-09 | 华润三九(雅安)药业有限公司 | 参附注射液、其制备方法及其制备系统 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100360119C (zh) * | 2003-09-04 | 2008-01-09 | 雅安三九药业有限公司 | 治疗气虚阳脱的参附缓释包衣微孔膜包衣片及其制备方法 |
CN1689593A (zh) * | 2004-04-29 | 2005-11-02 | 哈药集团中药二厂 | 一种注射用参附粉针剂的制备方法 |
CN1583095A (zh) * | 2004-06-16 | 2005-02-23 | 四川乐山三民药物科技开发有限公司 | 参银注射剂及制备方法 |
-
2006
- 2006-09-12 CN CN2006101535771A patent/CN1951432B/zh not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101697986B (zh) * | 2007-05-31 | 2012-01-25 | 北京和润创新医药科技发展有限公司 | 一种用离子交换树脂分离长春花总生物碱的方法 |
CN102283913A (zh) * | 2011-09-08 | 2011-12-21 | 四川省中医药科学院 | 附子提取物及其应用 |
CN113281448A (zh) * | 2021-05-22 | 2021-08-20 | 江西中医药大学 | 基于心源性休克大鼠模型的代谢组学分析方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1951432B (zh) | 2011-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101185671B (zh) | 从核桃树皮中提取的抗肿瘤药物及其制备方法 | |
CN101375990B (zh) | 一种用于治疗心血管疾病的组合物及其制备方法 | |
CN101119740B (zh) | 中药地榆及其提取物在制备升高红细胞和血红蛋白药物中的应用 | |
CN1951432B (zh) | 参附组合物、制剂及其制备方法和用途 | |
CN104840527A (zh) | 一种含远志糖酯和人参皂苷的组合物及用途 | |
CN101084952B (zh) | 一种刺五加皂苷提取物的制备方法 | |
CN1923241B (zh) | 包括淫羊藿提取物、钩藤提取物、天麻素的药物组合物及其制备方法和应用 | |
CN101085802B (zh) | 一种三七总皂苷的制备方法 | |
CN102526147B (zh) | 一种三七总皂苷的纯化方法及其制剂 | |
JPH0789863A (ja) | ジンセノサイド−Reの単離精製法及び該化合物を主成分とする抗不整脈剤 | |
CN100384429C (zh) | 一种用于治疗心脑血管疾病的胶囊及其制备方法和应用 | |
CN1698717B (zh) | 一种中药复方脂肪乳注射液及其制备方法 | |
CN1788758A (zh) | 中药地榆及其提取物在制备升高红细胞和血红蛋白药物中的应用 | |
CN108524811A (zh) | 降低尿酸、胆固醇、治疗三高的中药组合物及其制法 | |
CN101732578A (zh) | 一种治疗原发性高血压的药物组合物及其制备方法和用途 | |
CN101084954A (zh) | 一种西洋参总皂苷的制备方法 | |
CN101085191B (zh) | 一种生脉有效部位提取物及其制剂 | |
CN100448457C (zh) | 中药党参有效部位及其制剂与医药用途和制备方法 | |
CN114642707A (zh) | 含有灯盏细辛、人参、麦冬、五味子的药物组合物 | |
CN101249129B (zh) | 一种治疗糖尿病的中药提取物组合物及其医药用途 | |
CN109223739A (zh) | 一种组合物及其制备方法和应用 | |
CN100560569C (zh) | 一种莲子心生物碱提取物、其制备方法及其在制备心脑血管疾病药物中的应用 | |
CN102512469A (zh) | 人参地上部分的半仿生加液泛提取及制备方法 | |
CN102351874B (zh) | 一种具有药用活性的新化合物灯盏细辛酯 | |
CN101974012A (zh) | 一种具有药用活性的新化合物灯盏细辛酸乙酯 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Sun Lifang Inventor after: An Fengmin Inventor after: Han Kun Inventor after: Ma Chengjun Inventor after: Jiang Wanglin Inventor after: Liu Guang Inventor before: Ma Chengjun Inventor before: Jiang Wanglin Inventor before: Liu Guang |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: MA CHENGJUN JIANG WANGLIN LIU GUANG TO: SUN LIFANG AN FENGMIN HAN KUN MA CHENGJUN JIANG WANGLIN LIU GUANG |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170721 Address after: 264670, No. 15, pioneering Road, hi tech Zone, Shandong, Yantai Patentee after: Shandong Luye Pharma Co., Ltd. Address before: 264003 Laishan, Shandong Province Bao Road, No. 9 District, No. Patentee before: Luye Natural Medicinal Research Developing Co., Ltd., Shandong Prov. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111221 Termination date: 20180912 |
|
CF01 | Termination of patent right due to non-payment of annual fee |